FOSUN PHARMA (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Deferasirox tablets and granules (hereinafter referred to as “the drugs”). These drugs are independently developed chemical drugs by the group (the company and its subsidiaries). The approved indications include treatment for (1) chronic iron overload in β-thalassemia patients above 2 years old due to frequent blood transfusions, and (2) chronic iron overload in non-transfusion-dependent thalassemia syndrome patients aged 10 years and above. As of September 2025, the group has invested approximately RMB 24.55 million (unaudited) in research and development for these drugs. According to the latest IQVIA CHPA data, the sales revenue of Deferasirox formulations in mainland China (excluding Hong Kong, Macau, and Taiwan) is expected to be approximately RMB 128 million in 2024.